Tesamorelin + Ipamorelin Blend
Stabilized GHRH (Tesamorelin) + ghrelin receptor agonist (Ipamorelin) blend
- Class
- GH secretagogue blend
- Half-life
- Both ~30 min – 2h
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Mixed / early human
Overview
Tesamorelin + Ipamorelin is the body-comp variant of the CJC+Ipa stack. The pharmacology is identical in shape (one GHRH-receptor driver paired with one ghrelin-receptor pulser), but Tesamorelin carries something CJC-1295 doesn't: actual FDA approval. Egrifta (tesamorelin) is approved for visceral-fat reduction in HIV-associated lipodystrophy, with multiple Phase-3 trials showing ~15-18% visceral-fat loss over 26 weeks at 2 mg/day.
The Ipamorelin half is the same ghrelin-receptor pulse it provides in CJC+Ipa — adds a discrete GH burst on top of the GHRH baseline tesamorelin establishes. Net effect: bigger, cleaner GH pulses than either alone, with the body-comp credential users want when picking a GH-stack for fat loss rather than recovery.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Tesamorelin alone is FDA-approved (Egrifta); the BLEND with Ipamorelin is not — research-market product.
- Insulin sensitivity drops over months on chronic GH-stack use. Cycle 12-on / 4-off mitigates.
- Avoid in active cancer or family history of pituitary disease.
+ 2 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching Tesamorelin + Ipamorelin Blend.
- IGF-1 (rises 30-50% over baseline at typical doses)
- Fasting glucose / HbA1c (GH antagonises insulin over months)
- Visceral / abdominal body composition (DEXA + waist circumference if tracking the body-comp goal)
- Sleep quality (subjective — most users notice changes here within 1-2 weeks)
- Hand / foot tingling (IGF-1 overshoot warning sign)
Frequently asked questions
What is Tesamorelin + Ipamorelin Blend?
Stabilized GHRH (Tesamorelin) + ghrelin receptor agonist (Ipamorelin) blend. Tesamorelin + Ipamorelin is the body-comp variant of the CJC+Ipa stack. The pharmacology is identical in shape (one GHRH-receptor driver paired with one ghrelin-receptor pulser), but Tesamorelin carries something CJC-1295 doesn't: actual FDA approval. Egrifta (tesamorelin) is approved for visceral-fat reduction in HIV-associated lipodystrophy, with multiple Phase-3 trials showing ~15-18% visceral-fat loss over 26 weeks at 2 mg/day.
How is Tesamorelin + Ipamorelin Blend administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of Tesamorelin + Ipamorelin Blend?
Both ~30 min – 2h — Tesamorelin sc ~26 min · Ipamorelin sc ~2 h. Daily dosing, typically pre-bed to ride the natural night-time GH pulse..
Is Tesamorelin + Ipamorelin Blend approved for human use?
Tesamorelin + Ipamorelin Blend is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for Tesamorelin + Ipamorelin Blend?
Evidence tier: Mixed / early human. Tesamorelin's pivotal trials (Falutz 2007, Stanley 2014) used 2 mg/day sc over 26 weeks — visceral fat dropped ~15-18% with maintained subcutaneous fat. The trial population was HIV-lipodystrophy, NOT general body-comp users.
What is commonly monitored when researching Tesamorelin + Ipamorelin Blend?
Commonly tracked markers + signals: IGF-1 (rises 30-50% over baseline at typical doses), Fasting glucose / HbA1c (GH antagonises insulin over months), Visceral / abdominal body composition (DEXA + waist circumference if tracking the body-comp goal), Sleep quality (subjective — most users notice changes here within 1-2 weeks), Hand / foot tingling (IGF-1 overshoot warning sign).
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.